PKP2 expression is upregulated in bladder, brain and lung cancer cells [1–3]. Overexpression of PKP2 in breast and lung cancer cells increases cell proliferation and migration [4,5]. A siRNA/shRNA-mediated knock down in different cancer cell lines inhibits proliferation and migration [1–5]. A knockout of PKP2 in human primary adipocytes result in senescence of the cells [6].
In a murine xenograft assay, the injection of different cancer cell lines with RNAi-mediated PKP2 knock down reduced tumour sizes compared to non-target controls [2,4,5].
Die Ursächliche Beteiligung an der Entstehung von Tumoren ist nicht gezeigt.
[1] Zhang, D. et al., Neuropathology, 2017, 37 (3), 207–216. doi: 10.1111/neup.12363.
[2] Wu, Y. et al., Cancer Manag Res, 2021, 13, 559–570. doi: 10.2147/CMAR.S281663.
[3] Takahashi, H. et al., Urology, 2012, 79 (1), 240.e1-8. doi: 10.1016/j.urology.2011.08.049.
[4] Hao, X.-L. et al., Pathol Res Pract, 2019, 215 (7), 152438. doi: 10.1016/j.prp.2019.152438.
[5] Arimoto, K.-i. et al., Mol Cell Biol, 2014, 34 (20), 3843–3854. doi: 10.1128/MCB.00758-14.
[6] Lluch, A. et al., Nat Commun, 2023, 14 (1), 5106. doi: 10.1038/s41467-023-40596-0.
